右旋溴苯那敏马来酸盐 | 2391-03-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 右旋溴苯那敏马来酸盐
• 中文别名: 马来酸右溴苯那敏
• 英文名称: S-brompheniramine maleate
• 英文别名: Dexbrompheniramine maleate；(+)-brompheniramine maleate；(S)-brompheniramine maleate；d-brompheniramine maleate；(3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine;(Z)-but-2-enedioic acid
• CAS: 2391-03-9
• 化学式: C₄H₄O₄*C₁₆H₁₉BrN₂
• 分子量: 435.318
• InChiKey: SRGKFVAASLQVBO-DASCVMRKSA-N

物化性质

• 熔点：
  132-134℃
• 溶解度：
  甲醇（微溶）、水（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  3.64
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  90.7
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险品标志：
  T
• 危险类别码：
  R25
• 危险品运输编号：
  UN 2811 6.1/PG 3
• WGK Germany：
  3
• RTECS号：
  US4026200
• 危险标志：
  GHS06
• 危险性描述：
  H301
• 危险性防范说明：
  P301 + P310

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : (+)-Brompheniramine maleate salt
CAS-No. : 2391-03-9
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Toxic if swallowed.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R25 Toxic if swallowed.
S-phrase(s)
S22 Do not breathe dust.
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
S45 In case of accident or if you feel unwell, seek medical advice immediately
(show the label where possible).
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C16H19BrN2 · C4H4O4
Molecular Weight : 435,31 g/mol
Component Concentration
(S)-2-[p-Bromo-α-[2-(dimethylamino)ethyl]benzyl]pyridinium (Z)-maleate (1:1)
CAS-No. 2391-03-9 -
EC-No. 219-236-2

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Dermatitis
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate
ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
LD50 Oral - rat - 191 mg/kg
Remarks: Sense Organs and Special Senses (Nose, Eye, Ear, and Taste):Eye:Mydriasis (pupilliary
dilation). Behavioral:Tremor. Behavioral:Convulsions or effect on seizure threshold.
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Toxic if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
Dermatitis
Additional Information
RTECS: US4026200

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. ((S)-2-[p-Bromo-α-[2-
(dimethylamino)ethyl]benzyl]pyridinium (Z)-maleate (1:1))
TOXIC SOLID, ORGANIC, N.O.S. ((S)-2-[p-Bromo-α-[2-
IMDG:
(dimethylamino)ethyl]benzyl]pyridinium (Z)-maleate (1:1))
Toxic solid, organic, n.o.s. ((S)-2-[p-Bromo-α-[2-(dimethylamino)ethyl]benzyl]pyridinium (Z)-
IATA:
maleate (1:1))
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为产物：
  描述：

  马来酸溴苯那敏 在 sodium dihydrogenphosphate 、 磷酸 作用下， 以 甲醇 、 水 为溶剂， 生成 右旋溴苯那敏马来酸盐 、 (R)-brompheniramine maleate
  参考文献：
  名称：

  离子液体与羟丙基-β-环糊精联合使用通过毛细管电泳对十种药物进行对映体分离

  摘要：

  在本研究中，羟丙基β环糊精和离子液体（1-乙基-3- methylimidazolium-升乳酸盐）在毛细管电泳中用作添加物，用于10种分析物的对映体分离，包括氧氟沙星，盐酸普萘洛尔，盐酸二氧异丙嗪，盐酸异丙肾上腺素，马来酸氯苯那敏，利拉唑，托乙酰胺，氨氯地平苯磺酸钠，溴苯那敏马来酸。研究了离子液体浓度，盐效应，阳离子和离子液体对对映体分离的影响，结果证明羟丙基-β-环糊精与离子液体以及离子液体的阳离子部分存在协同作用。在提高分辨率方面发挥了重要作用。使用开发的双系统，可以很好地分离10种分析物的所有对映体，分离度分别为5.35、1.76、1.85、2.48、2.88、1.43、5.45、4.35、2.76和2。98。此外，所提出的方法还用于测定对映体的纯度。小号氧氟沙星在选择性，重复性，线性范围，准确度，精密度，检测限（LOD）的限制，和质量（LOQ）的极限方面的方法的验证之后。手性25

  DOI：

  10.1002/chir.22168

文献信息

• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Modified azole compounds as antifungal and antibacterial agents
  申请人：Borgers Marcel

  公开号：US20080032994A1

  公开（公告）日：2008-02-07

  The present invention relates to the compounds of formula (I), their preparation and use as antifungal and/or antibacterial agents. where the values for R 1 , R 2 , R 3 , R 4 , R 5 and A are as defined herein.

  本发明涉及式(I)的化合物，其制备和用作抗真菌和/或抗菌剂，其中R1、R2、R3、R4、R5和A的值如本文中所定义。
• COMPOUNDS USEFUL AS MODULATORS OF TRPM8
  申请人：Senomyx, Inc.

  公开号：US20170096418A1

  公开（公告）日：2017-04-06

  The present disclosure relates to compounds which are useful as cooling sensation compounds.

  本公开涉及作为冷感化合物有用的化合物。
• Preparation of a β-Cyclodextrin-Based Open-Tubular Capillary Electrochromatography Column and Application for Enantioseparations of Ten Basic Drugs
  作者：Linlin Fang、Jia Yu、Zhen Jiang、Xingjie Guo

  DOI：10.1371/journal.pone.0146292

  日期：——

  background electrolyte as chiral additive to expect a possible synergistic effect occurring and resulting in a better separation. Fortunately, significant improvement in enantioselectivity was obtained for ten pairs of drug enantiomers. Then, the effects of β-cyclodextrin concentration and background electrolyte pH on the chiral separation were investigated. With the developed separation mode, all the

  采用(3-巯基丙基)三甲氧基硅烷预衍生化将β-环糊精修饰的金纳米颗粒化学固定在新表面上，制备了开管毛细管电色谱柱。通过透射电子显微镜、扫描电子显微镜、红外光谱和紫外可见光谱对合成的纳米粒子和制备的柱进行了表征。当该柱用作手性固定相时，十种模型碱性药物没有观察到对映选择性。因此，将β-环糊精作为手性添加剂添加到背景电解质中，以期望可能发生协同效应并导致更好的分离。幸运的是，十对药物对映体的对映选择性得到了显着改善。然后，研究了β-环糊精浓度和背景电解质pH对手性分离的影响。采用所开发的分离模式，对佐匹克隆、马来酸氯苯那敏、马来酸溴苯那敏、盐酸二氧丙嗪、卡维地洛的所有对映体（文拉法辛除外）进行了基线分离，分辨率分别为 4.49、1.68、1.88、1.57、2.52、2.33、3.24、1.63 和 3.90分别为氢溴酸后马托品、甲基溴后马托品、文拉法辛、盐酸西布曲明和硫酸特布他林。此外，还讨论了所涉及的可能的分离机制。